ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus
Castle Biosciences announced three studies of its TissueCypher Barrett's Esophagus test being presented at the ACG 2026 Annual Scientific Meeting in Nashville. A multi-center cohort study found TissueCypher results changed management recommendations for 96% of patients, including extending surveillance intervals and prompting endoscopic eradication therapy in patients whose biopsies showed no dysplasia. Two case reports showed the test flagged high five-year progression risk (62% and 47%) in patients presumed low-risk on histology, leading to earlier intervention and detection of previously missed high-grade dysplasia.
Key figures
- Patients studied
- more than 8,000
- Cohens kappa vs pib
- 0.04
- Management change rate
- 96% of multi-center cohort
- Tissuecypher risk split
- 83% low risk / 17% intermediate-high risk
- Peer reviewed publications
- more than 17
- High risk case 1 probability
- 62% five-year progression probability
- High risk case 2 probability
- 47% five-year progression probability
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.